

# RICT 2013

## Drug Discovery and Selection

### Confirmed Speakers

#### Confirmed Speakers To Date

##### Natural Products as Leads for Drug Discovery



Prof. Karl-Heinz ALTMANN  
(ETH ZURICH, Zürich, Switzerland)

##### Strategies and Challenges for the Next Generation of Therapeutic Antibodies and Derivatives



Dr Alain BECK  
(PIERRE FABRE, St Julien-en-Genevois, France)

##### Beyond Antithrombotics: Synthetic Approaches to Unravel New Therapeutic Potentials for Glycosaminoglycans



Prof. David BONNAFFÉ  
(UNIVERSITY PARIS-SUD, Orsay, France)

##### Systemic Safety by Design: a Novel Retinoic Acid Receptor Agonist for Dermatological Indications with Specific Design Parameters for Topical Administration to Manage Safety



Dr Claire BOUIX-PETER  
(GALDERMA R&D, Sophia-Antipolis, France)

##### The Discovery of Small Molecule Inhibitors of Jumonji Enzymes: Probing the Epigenome



Dr Jack BROWN  
(EPINOVA DPU, II TAU, GLAXOSMITHKLINE, Stevenage, United Kingdom)

##### Antibody-Drug Conjugates: A Promising new Paradigm in Cancer Therapy



Dr Ravi CHARI  
(IMMUNOGEN, Waltham, United States)

##### Structure and Fragment Based Drug Design for G Protein-Coupled Receptors



Dr Miles CONGREVE  
(HEPTARES, Welwyn Garden City, United Kingdom)

##### Fragment Screening and Drug Design with Fluorine NMR Spectroscopy



Dr Claudio DALVIT  
(UNIVERSITY OF NEUCHÂTEL, Neuchâtel, Switzerland)

##### Discovery of Highly Potent, Selective and Efficacious Cathepsin S Inhibitors

# RICT 2013

## Drug Discovery and Selection

### Confirmed Speakers



Dr Wolfgang HAAP  
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

#### Discovery and Optimization of Indoline Pyrimidone PI3Kb Inhibitors for the Treatment of PTEN-deficient Cancers



Dr Frank HALLEY  
(SANOFI, Vitry-sur-Seine, France)

#### DAAO Inhibitors as Clinical Candidates



Dr Michele HEFFERNAN  
(SUNOVION PHARMACEUTICALS, Marlborough, United States)

#### High Confidence Target and Pathway Prediction Using a Robust Chemogenomic Platform



Dr Stephen HELLIWELL  
(NOVARTIS, Basel, Switzerland)

#### The European Lead Factory - A Novel Discovery Partnership Model



Dr Jörg HUESER  
(BAYER PHARMA, Wuppertal, Germany)

#### Targeted Cancer Chemotherapy: Developing NextGen Antibody Drug Conjugates & Key factors that Influence ADC Therapeutics



Dr Jagath Reddy JUNUTULA  
(GENENTECH, South San Francisco, United States)

#### ADMET Modelling: Where is it Worth the Effort?



Dr Richard LAW  
(EVOTEC, Abingdon, United Kingdom)

#### Of Ionic Channels, Venom Toxins and Other Natural Substances ... and Diseases



Prof. Michel LAZDUNSKI  
(INSTITUT DE PHARMACOLOGIE MOLECULAIRE ET CELLULAIRE (IPMC), Nice, France)

#### Improving Compound Quality in Medicinal Chemistry



Dr Paul LEESON  
(ASTRAZENECA, Nuneaton, United Kingdom)

#### SOM230: A New Therapeutic Modality for Cushing's Disease

# RICT 2013

## Drug Discovery and Selection

### Confirmed Speakers



Dr Ian LEWIS  
(NOVARTIS, Basel, Switzerland)

#### How Animal Venoms Help to Understand Pain: Acid-Sensing Ion Channels in the Pain Pathway



Dr Eric LINGUEGLIA  
(CNRS-UNIVERSITY OF NICE SOPHIA ANTIPOLIS, Valbonne, France)

#### Developing New Tools for Cancer Diagnostics and Therapeutics: Fluorescent Peptide Biosensors of Cyclin-Dependent Kinases



Dr May MORRIS  
(CENTRE DE RECHERCHE EN BIOCHIMIE MACROMOLÉCULAIRE (CRBM) - CNRS, Montpellier, France)

#### Validation of Protein Kinases as Drug Targets in the African Trypanosome



Prof. Jeremy MOTTRAM  
(UNIVERSITY OF GLASGOW, Glasgow, United Kingdom)

#### All in Good Time, Exploiting Residence Time to Improve Fragment Based Drug Discovery



Dr James MURRAY  
(VERNALIS, Cambridge, United Kingdom)

#### Ion Channel Drug Discovery: a Medicinal Chemistry Perspective



Dr Robert OWEN  
(PFIZER NEUSENTIS, Cambridge, United Kingdom)

#### GLPG0974, a FFA2 Antagonist from Hit to Clinic



Dr Laurent SANIERE  
(GALAPAGOS, Romainville, France)

#### Discovery of Potent and Selective Inhibitors of the Cardiac Sodium/Calcium Exchanger (NCX-1)



Dr Hartmut SCHIROK  
(BAYER, Wuppertal, Germany)

#### Molecular Networks : Drug Action and Genome-Informed Medicine



Prof. Giulio SUPERTI-FURGA  
(RESEARCH CENTER FOR MOLECULAR MEDICINE (CEMM), Vienna, Austria)

#### Drugs for Bad Bugs - Strategies to Address Infections by Multidrug-resistant Bacteria

# RICT 2013

## Drug Discovery and Selection

### Confirmed Speakers



Dr Jean-Philippe SURIVET  
(ACTELION, Allschwil, Switzerland)

### Allosteric Modulation of the Chemokine Receptor CXCR3



Dr Nuka TSCHAMMER  
(UNIVERSITY OF ERLANGEN-NÜRNBERG, Erlangen, Germany)

### Drug Discovery for Diseases of the Developing World



Prof. Paul WYATT  
(UNIVERSITY OF DUNDEE, Dundee, United Kingdom)